Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alligator Bioscience AB ( (SE:ATORX) ) just unveiled an announcement.
Alligator Bioscience announced that it will present data from its Phase 1 trial of mitazalimab in combination with dendritic cell vaccination at the ESMO Congress 2025. This study, conducted by Erasmus MC Cancer Institute, assesses the safety and efficacy of this combination therapy in patients with metastatic pancreatic cancer, potentially impacting future treatment approaches and the company’s position in the oncology market.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company based in Lund, Sweden, specializing in the development of clinical-stage tumor-directed immuno-oncology antibody drugs. The company focuses on the CD40 receptor to enhance T cell priming and counteract the immunosuppressive tumor microenvironment, offering potential benefits for cancer patients. Their lead drug candidate, mitazalimab, is advancing towards Phase 3 development and has shown promising results in metastatic pancreatic cancer.
Average Trading Volume: 418,749
Technical Sentiment Signal: Sell
Current Market Cap: SEK186.8M
See more insights into ATORX stock on TipRanks’ Stock Analysis page.